聚焦超声机械破坏使ER+乳腺癌细胞对他莫昔芬重新敏感
该研究评估聚焦超声(FUS)机械破坏对他莫昔芬耐药的ER+乳腺癌细胞的再增敏作用。耐药与非耐药ER+乳腺癌细胞及患者来源异种移植瘤接受他莫昔芬、FUS或联合处理,检测凋亡、增殖、ER基因表达与活性及形态学改变。FUS机械破坏耐药细胞后上调ERα编码基因表达并长期再增敏他莫昔芬;联合处理的患者来源异种移植瘤活力和增殖显著降低,肿瘤细胞及细胞外基质出现明显结构损伤。
要点
- FUS机械破坏他莫昔芬耐药ER+乳腺癌细胞,上调ERα编码基因表达并长期再增敏他莫昔芬。
- 患者来源异种移植瘤经他莫昔芬联合FUS处理后,肿瘤活力和增殖显著降低。
- 联合处理组肿瘤细胞及细胞外基质出现强烈结构损伤。
核心结论
- FUS可通过机械破坏使ER+乳腺癌细胞对他莫昔芬再增敏,从而改善ER+乳腺癌治疗。
研究设计与样本
- 研究论文;使用耐药与非耐药ER+乳腺癌细胞及患者来源ER+乳腺癌异种移植瘤,分别给予他莫昔芬、FUS或联合处理,检测凋亡、增殖率、雌激素受体基因表达与活性及形态学改变。
关键影像表现/征象
- FUS引起他莫昔芬耐药乳腺癌细胞的机械破坏。
- 他莫昔芬联合FUS处理的患者来源异种移植瘤显示肿瘤活力和增殖显著降低。
- 联合处理组肿瘤细胞及细胞外基质出现强烈结构损伤。
诊断标准与关键数值
- FUS机械破坏后上调ERα编码基因表达并长期再增敏细胞对他莫昔芬的敏感性。
- 他莫昔芬联合FUS使患者来源异种移植瘤活力和增殖显著降低,并造成肿瘤细胞及细胞外基质强烈结构损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Tamoxifen is the most used agent to treat estrogen receptor-positive (ER+) breast cancer (BC). While it decreases the risk of cancer recurrence by 50%, many patients develop resistance to this treatment, culminating in highly aggressive disease. Tamoxifen resistance comes from the repression of ER transcriptional activity that switches the cancer cells to proliferation via nonhormonal signaling pathways. Here, we evaluate a potential strategy to overcome tamoxifen resistance by focused ultrasound (FUS), a noninvasive approach for the mechanical excitation of cancer cells.
METHODS: Resistant and nonresistant ER+ BC cells and xenografts from patients with ER+ BC were treated with tamoxifen, FUS or their combination. The apoptosis, proliferation rate, gene expression and activity of estrogen receptor, and morphological changes were measured in treated cells and tissues.
RESULTS: FUS caused the mechanical disruption of tamoxifen-resistant BC cells that in turn led to the upregulation of ERα-encoding gene expression and long-term re-sensitization of the cells to tamoxifen. Patient-derived xenografts treated with Tamoxifen and FUS demonstrated a significant reduction in tumor viability and proliferation and a strong structural damage to tumor cells and extracellular matrix.
CONCLUSION: FUS can improve ER+ BC treatment by re-sensitizing the cancer cells to tamoxifen.
引用
- Murad HY, Sabol RA, Nyiramana J, et al. Mechanical Disruption by Focused Ultrasound Re-sensitizes ER+ Breast Cancer Cells to Hormone Therapy. Ultrasound Med Biol. 2024. PMID: 39277462. doi:10.1016/j.ultrasmedbio.2024.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。